on PL BioScience GmbH
PL BioScience Unveils Unique Gamma-irradiated Human Platelet Lysate
PL BioScience GmbH, based in Aachen, Germany, has announced the launch of ELAREM™ Ultimate-FD PLUS, a groundbreaking gamma-irradiated Human Platelet Lysate (HPL). This product, manufactured using a patented process, represents a significant step forward in cell culture supplements, particularly for regenerative medicine and cell therapies.
Serving as a safer alternative to Fetal Bovine Serum, this gamma-irradiated HPL aligns with EU regulations and supports the demand for xeno-free, virus-inactivated, ethically sourced supplements. The innovative process reduces safety risks associated with traditional animal-derived products, offering a stable and ethically responsible option for global manufacturers.
ELAREM™ Ultimate-FD PLUS is positioned to meet the stringent requirements of cell manufacturing applications, including potential clinical trial use, by providing a fibrinogen-depleted, anticoagulant-free product in line with GMP standards.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PL BioScience GmbH news